Essential Strategies for Eliminating HCV Among Persons With Current or Recent Injection Drug Use
  • CME
  • CE

This CME/CE-certified interactive video module provides in-depth expert perspectives on critical barriers impeding the diagnosis, treatment, and cure of HCV infection among persons who inject drugs along with an analysis of critical strategies for overcoming these challenges to address both HCV and other important healthcare needs of this vulnerable population.
Mark S. Sulkowski, MD
Program Director
Arthur Kim, MD
Christian Ramers Headshot
Christian B. Ramers, MD, MPH
Jeannette M. Tetrault, MD, FACP, FASAM
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Registered Nurses: 1.7 Nursing contact hours
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: April 2, 2019 Expiration: April 1, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Devise strategies to overcome barriers to HCV treatment for PWIDs
  • Provide appropriate patient counsel on HCV reinfection risk and prevention/harm reduction strategies for PWIDs who are cured of current HCV infection
  • Apply interventions that support HCV elimination efforts among PWIDs

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Mark S. Sulkowski, MD

Professor of Medicine
Medical Director,
Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Merck and funds for research support (paid to Johns Hopkins University) from AbbVie, Assembly Bio, Gilead Sciences, and Proteus Digital Health.

Faculty

Arthur Kim, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospiatl
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has received consulting fees from Biomarin.
Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Assistant Medical Director
Division of Research/Special Populations
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from AbbVie and Gilead Sciences; fees for non-CME/CE services from AbbVie, Gilead Sciences, and Merck; and funds for research support from Gilead Sciences.
Jeannette M. Tetrault, MD, FACP, FASAM

Associate Professor of Medicine
Department of Internal Medicine
Program Director
Addiction Medicine Fellowship
Yale School of Medicine
New Haven, Connecticut

Jeanette M. Tetrault, MD, FACP, FASAM, has no real or apparent conflicts of interest to report.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

The ASAM planners and managers have nothing to disclose.

The INHSU planners and managers have nothing to disclose.

The HealthHCV planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Goal

The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, International Network for Hepatitis in Substance Users and HealthHCV.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-620-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 02, 2019, through April 01, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

TasP commentary from Alessio Aghemo, MD, PhD, on improving PWID access to HCV treatment by changing restrictive regulatory barriers in Italy

Alessio Aghemo, MD, PhD Released: August 2, 2019

CME/CE/CPE-certified video on strategies for bringing HCV cure to more patients, led by Nancy Reau, MD, from the CCO Hepatitis Annual Meeting

Ira M. Jacobson, MD
Program Director
Jordan J. Feld, MD, MPH Paul Y. Kwo, MD Marion G. Peters, MD, FRACP Nancy Reau, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: August 1, 2019 Expiration: July 31, 2020

Expert commentary from W. David Hardy, MD, featuring guidance on HCV screening and treatment as prevention in MSM, provided by Clinical Care Options

W. David Hardy, MD Released: July 18, 2019

Clinical Care Options’ expert audio from Stacey Trooskin, MD, PhD, outlining new models of care to improve HCV management for people who inject drugs

Stacey Trooskin, MD, PhD Released: July 10, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?